<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3436">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03062176</url>
  </required_header>
  <id_info>
    <org_study_id>HM20007618</org_study_id>
    <nct_id>NCT03062176</nct_id>
  </id_info>
  <brief_title>Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With End-stage Renal Disease (E-HART)</brief_title>
  <acronym>E-HART</acronym>
  <official_title>Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With End-stage Renal Disease (E-HART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Interleukin-1 Blockade for the Treatment of Heart Failure in Patients with End-stage
      Renal Disease (End-stage renal disease and Heart fAilure - Anakinra Remodeling Trial) is a
      Phase 2, single-arm trial designed to estimate the effect of anakinra, a recombinant human
      Interleukin-1 (IL-1) receptor antagonist, on cardiorespiratory fitness in patients with
      end-stage renal disease and heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak oxygen consumption (PVO2)</measure>
    <time_frame>6 months</time_frame>
    <description>Peak oxygen consumption during cardiopulmonary exercise</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Hospitalization</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with a hospitalization for heart failure during the 6 months of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Heart Failure, Systolic</condition>
  <condition>Renal Disease, End Stage</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra (Kineret)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>Anakinra (Kineret)</description>
    <arm_group_label>Active Treatment</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  18 years or older

          -  Chronic heart failure

          -  Left ventricular ejection fraction less than 50%

          -  C-reactive protein greater than or equal to 2 mg/L

          -  Maintenance hemodialysis

        Exclusion Criteria:

          -  Inability to complete maximal cardiopulmonary exercise testing

          -  Need for urgent or emergent care

          -  Recent use of immunosuppressant, anti-inflammatory therapies or active rheumatologic
             disease

          -  Allergy to rubber, latex, Escherichia coli or anakinra
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin W Van Tassell, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin W Van Tassell, PharmD</last_name>
    <email>bvantassell@vcu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin W Van Tassell, PharmD</last_name>
      <phone>804-828-4583</phone>
      <email>bvantassell@vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Antonio Abbate, MD, PhD</last_name>
      <phone>804-828-0513</phone>
      <email>aabbate@vcu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>January 25, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>End-stage renal disease</keyword>
  <keyword>Interleukin-1</keyword>
  <keyword>Interleukin-1 receptor antagonist</keyword>
  <keyword>Metabolomics</keyword>
  <keyword>Lipidomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
